Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Mirati Therapeutics is at the forefront of precision medicine, with a pipeline full of drugs targeting tumors expressing specific mutations.
The company replaced its CEO and reported strong revenue growth.
The company presented phase 2 data from its non-small cell lung cancer therapy.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.